sedanamedical
Bringing inhaled sedation to intensive care

Year-end report

January-December 2025

Sedana Medical AB (publ)

”Positive EBITDA in our ex-US business”

Johannes Doll, President & CEO

Q1 Q2 Q3 **Q4**

Financial summary

Fourth quarter 2025

- Net sales for the quarter totaled MSEK 51.8 (49.2), equivalent to an increase of 5% compared to the corresponding quarter in 2024. At constant exchange rates, sales increased by 11%.
- Gross profit amounted to MSEK 37.6 (34.2), corresponding to a gross margin of 73% (69%).
- Net sales excluding contract manufacturing totaled MSEK 50.5 (48.4), equivalent to an increase of 4% compared to the corresponding quarter in 2024. At constant exchange rates, sales increased by 10%.
- Earnings before interest, taxes, depreciation and amortisation (EBITDA) totaled MSEK 0.1 (-5.5), corresponding to an EBITDA margin of 0.1% (-11%). EBITDA ex-US amounted to MSEK 4.0 (-1.2), equivalent to a margin of 8% (-3%).
- Operating income (EBIT) totaled MSEK -6.1 (-11.1), corresponding to an EBIT margin of -12% (-22%).
- Net income for the period amounted to MSEK -10.1 (8.5), and earnings per share before and after dilution were SEK -0.10 (0.09). Operating income improved by MSEK 5.0 compared to the corresponding quarter last year, but net financial items decreased by MSEK 23.6, resulting in a reduction in net income of MSEK 18.7.
- Cash and cash equivalents amounted to MSEK 91.0 at the end of the quarter, compared with MSEK 112.0 at the beginning of the quarter. Cash and cash equivalents were affected by unrealised currency effects of MSEK -1.9 (16.2).
- Cash flow from operating activities before changes in working capital totaled MSEK 0.2 (6.3) for the quarter. Cash flow was positively impacted by received interest of MSEK 3.3 (11.8).
- Total cash flow for the quarter improved to MSEK -19.1 (-48.6), mainly resulting from improved EBITDA, reduced investments in intangible assets of MSEK -11.0 (-28.8) mainly referring to registration preparatory work in the USA, and that the comparator period includes net cash flow from the acquisition of Innovatif Cekal of MSEK -25.0.

January-December 2025

- Net sales for the period totaled MSEK 200.2 (178.8), equivalent to an increase of 12% compared to 2024. At constant exchange rates, sales increased by 16%.
- Net sales excluding contract manufacturing totaled MSEK 192.1 (178.0), equivalent to an increase of 8% compared to the corresponding period in 2024. At constant exchange rates, sales increased by 12%.
- Gross profit amounted to MSEK 142.7 (126.1), corresponding to a gross margin of 71% (71%).
- Earnings before interest, taxes, depreciation and amortisation (EBITDA) totaled MSEK -10.1 (-30.6), equivalent to an EBITDA margin of -5% (-17%). EBITDA ex-US amounted to MSEK 5.9 (-16.9), corresponding to a margin of 3% (-9%).
- Operating income (EBIT) totaled MSEK -32.2 (-52.2), corresponding to an EBIT margin of -16% (-29%).
- Net income for the year totaled MSEK -59.2 (-10.7), and earnings per share before and after dilution were SEK -0.60 (-0.11). Increased sales were offset by currency effects on cash, mainly held in USD, amounting to MSEK -23.1 (22.8), lower interest income of MSEK 3.4 (16.5), and unrealised exchange rate effects on intra-group receivables and liabilities MSEK 5.4 (3.0).
- Cash and cash equivalents and short-term investments totaled MSEK 91.0 at the end of the period, compared with MSEK 194.0 at the beginning of the year.
- Cash flow from operating activities totaled MSEK -12.8 (-11.8). Cash flow was affected by received interest of MSEK 3.4 (16.5) and a decrease in operating liabilities of MSEK -7.7 (0.2).
- Cash flow from investments in intangible assets amounted to MSEK -60.0 (-172.8) and mainly relates to registration preparatory work in the USA. Net cash flow from the acquisition of Innovatif Cekal amounted to MSEK -0.6 (-25.0).
- Total cash flow for the full year amounted to MSEK -79.8 (-60.0). Total cash flow excluding the repayment of short-term investments amounted to MSEK -79.8 (-215.3).





Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve patients' life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical was founded in 2005 and is listed on Nasdaq Stockholm. The company's head office is in Stockholm, Sweden.

CEO comments

Positive EBITDA in our ex-US business

2025 marked a successful year for Sedana Medical. We achieved first-time profitability in our core business outside the United States, demonstrating the strength of our transformed operating model and providing a solid, cash-generating foundation for further growth. At the same time, we made significant progress in reducing the risks related to US approval, with successful pivotal trials, FDA authorization of an Early Access Program and positive regulatory interactions.

Profitability in our core business outside the US

Coming out of the COVID-19 pandemic, we set an ambitious goal: to reach profitability in our core business before launching our therapy in the United States. We believed it was essential to build our US expansion on a stable, cash-generating platform - one that demonstrates proof of concept and helps us finance the upcoming US launch investments. Today, I am proud to say that we have delivered on that ambition during the full year 2025.

Reaching this point required a fundamental transformation of the company and a change of how we deploy resources across the organization. We streamlined corporate headquarters and non-customer-facing functions, while sharpening our focus on commercial execution and becoming significantly more customer-centric. Our support functions are now more effective with only half the number of employees, and at the same time we have built a larger and more impactful field force. We introduced a rigorous, data-driven investment approach, increasing resources in profitable and growing countries, and adjusting where performance has not yet met expectations. In parallel, the acquisition of our main supplier in Malaysia, Innovatif Cekal, strengthened our control over the value chain and improved the cost of goods for our main device.

As a result, we achieved 3% positive EBITDA margin in our core business outside the US for the full year 2025 and 8% in Q4. Also at the Group level, EBITDA improved by 12 percentage points year-on-year, and we even reached slightly positive EBITDA in the fourth quarter.

The full-year ex-US profit is the first in Sedana Medical's history as a listed company and marks a significant milestone. I would like to sincerely thank all colleagues across the organization for their dedication, resilience, and commitment in making this a reality.

Best Q4 sales to date despite lower ICU occupancy in Germany

Full-year sales reached 200 MSEK, corresponding to growth of 16% excluding exchange rate effects. Of this, 12% was organic growth, while 4% came from contract manufacturing activities at our plant in Malaysia.

I am pleased that all regions contributed positively to our growth on a full year basis, and that we reached new all-time high sales for each quarter during the year. Especially our direct markets outside Germany, including Spain, UK and France, stood out as the main growth driver. The Spanish success story over the last years demonstrates that a focused approach, targeted at establishing inhaled sedation as a standard therapy in high-potential hospitals, and engaging an increasing number of key opinion leaders believing in the benefits of the therapy, leads to rapidly increasing adoption rates – a model that we are replicating in other geographies.

While the overall result for the year is solid, it is worth noting that growth rates differed significantly between the first and second half of the year, with growth in H1 amounting to 22% excluding exchange rate effects, compared with only 9% in H2. In the fourth quarter, we delivered year-over-year growth of 11% excluding exchange rate effects, of which 10% was organic.

A key explanation for the differences during the year lies in lower ICU occupancy (fewer intensive care patients) during the second half of the year, which affected our performance most notably in Germany. According to data published by the Robert Koch Institute, the German flu season in Q1 and parts of Q2 2025 was longer and more pronounced than in 2024, providing tailwinds to our sales in the first half. Since May, the trend has reversed, and in Q4 specifically hospital admissions for severe acute respiratory infections requiring intensive care were approximately 20% lower year-on-year. As a result, German Q4 sales were 6% lower than in the previous year and the full year growth in Germany shrank to only 3%.

While seasonal swings in ICU activity are normal, our focus remains firmly on the factors we can influence. We continue to prioritize strong commercial execution, maximizing time in the field, concentrating resources on the highest-potential opportunities, and further improving the quality and impact of our customer interactions. I am convinced that these priorities will continue to drive sustainable growth going forward.

Important steps to reduce risks related to approval in the United States

The United States represents the single largest growth opportunity for Sedana Medical. Upon receiving US approval, we would expect our addressable market to quadruple versus today. This strong potential is driven by a higher number of ventilator beds, a clinical practice that favors intubation to a greater extent than in Europe, and a generally higher price level.

During 2025, we made several important advances to reduce the risk of our US approval. Both pivotal clinical trials met their primary endpoints and showed no new safety findings. In addition, the secondary endpoints offer several potential opportunities for meaningful differentiation versus current sedation practices, both in terms of patient benefits and health-economic advantages for hospitals. These may for instance include lower opioid requirements and a higher number of ICU-free days.

We were also encouraged by the FDA's approval of an Early Access Program, which allows use of our therapy in difficult-to-sedate patients when targeted sedation cannot be maintained with intravenous sedatives. Furthermore, in a positive pre-NDA meeting held in the fourth quarter, the FDA confirmed that the safety and efficacy data generated in our clinical program appear adequate to permit submission and review of a New Drug Application (NDA).

With these important steps completed, we believe we have significantly strengthened our position and reduced the key risks on the path toward bringing our therapy to patients in the United States. Our focus now is on finalizing the NDA dossier for submission mid-year, while further intensifying our planning and preparations for a potential US launch.

A pivotal year ahead

Reflecting on the achievements in 2025, I look into 2026 with optimism. With a therapy that offers compelling benefits for both patients and hospitals, a profitable and growing core business in Europe, and the opportunity to enter the United States as early as 2027, Sedana Medical is set up for success in the next phase of value creation.

I would like to thank all of you for your continued support and trust, and I look forward to updating you on our progress.

Johannes Doll, President and CEO

Significant events during the period

First quarter

- In February, Sedaconda (isoflurane) received an additional year of market protection, extending the protection period to 2032.
- In February, the company announced that its second pivotal US study, INSPiRE-ICU 2, had met its primary efficacy endpoint.

Second quarter

- In April, the company announced that the US FDA has authorized the company to initiate an Early Access Program for its treatment, which provides patients who meet the program's criteria access to the treatment before market approval.
- In June, the company announced that both of the company's pivotal US studies, INSPiRE-ICU 1 and INSPiRE-ICU 2, have shown a greater reduction of opioid doses compared to the control group and have therefore met their first key secondary endpoint.

Third quarter

- In July, the results of the IsoCOMFORT study were published in the scientific journal Lancet Respiratory Medicine.

Fourth quarter

- In November, Sedana Medical announced that the company has completed its pre-NDA meeting with the FDA. Broad alignment was achieved with the agency regarding the content of the forthcoming New Drug Application (NDA). The FDA confirmed that the safety and efficacy data from the clinical studies appear sufficient to enable submission and review of the NDA.
- In December, Sedana Medical announced that the company's CFO, Johan Spetz, has decided to leave the company.

Significant events after the period

- In January, Mikael Haag was appointed as the new CFO of Sedana Medical.

Market potential

With its innovative product portfolio for inhaled sedation, Sedana Medical is targeting mechanically ventilated patients in intensive care units. Geographically, Sedana Medical has a clear focus on today's direct markets in Europe (Germany, Spain, France, UK and Benelux) and its largest potential market, the United States.

The company's main device Sedaconda ACD is approved and sold in more than 40 countries. In 15 of these countries, Sedana Medical has approval for both its main device Sedaconda ACD and its proprietary pharmaceutical Sedaconda (isoflurane).

In today's direct markets in Europe, a bit less than 1 million intensive care patients annually require mechanical ventilation and sedation[1]. Based on this patient population, Sedana Medical sees a market potential for its current product portfolio of approximately 3-4 billion SEK.

In the United States, somewhat more than 2 million patients are mechanically ventilated and sedated each year[2]. Assuming a comparable approved label as in Europe, the market potential in the United States is estimated to be 10-12 billion SEK. The estimated market potential in the US assumes a relatively modest price difference compared to Europe. If Sedana Medical manages to obtain a price differential that is in line with other sedation therapies, the potential could increase accordingly.

In addition to the primary focus on Europe and the United States, Sedana Medical has distributors in more than 30 countries on all continents.

[1] Based on publicly available data per country and Sedana Medical's own research

[2] Based on externally performed market opportunity study

Strategic priorities

Sedana Medical has set 3 strategic priorities:

1. **Achieve lasting and profitable sales growth in Europe**
   Our market authorizations in 15 European countries make Sedana Medical the only company offering an approved therapy for inhaled sedation in intensive care. With a strong focus on commercial execution and a prudent investment philosophy that prioritizes profitable growth, we aim at making inhaled sedation a standard therapy.

2. **Maximize the opportunity in the United States**
   With more than 100,000 intensive care beds and a generally higher price level for sedation therapies, the United States represent our largest potential market. After completion of our Phase III clinical program, which has received FDA fast track designation, and assuming FDA approval, we aspire to launch our products through our own commercial infrastructure.

3. **Build a long-term profitable company**
   Sedana Medical's model with high gross margins and a concentrated customer base (hospitals with intensive care) favours attractive profitability as continue to grow sales. A key priority has been to turn the Ex-US business profitable, which was achieved for the full year 2025, so the US launch can be executed based on a stable financial platform. As we will gradually reach scale and grow the share of US sales, our long-term target is an EBITDA margin around 40%.

Financial guidance

For the full year 2026, we aim to achieve a mid-to-high single-digit ex-US EBITDA margin and approach positive EBITDA at the Group level.

Business update

Sales and commercial execution

Sedana Medical's vision is to make inhaled sedation the new standard of care in intensive care units (ICUs). Our therapy for inhaled sedation in the ICU consists of the unique medical device Sedaconda ACD, the pharmaceutical Sedaconda® (isoflurane) and accessories, and is being commercialized across Europe leveraging our own sales teams, and globally via distributors. We are focused on building a stronger commercial company by directing our investments towards profitable growth opportunities and enhancing the effectiveness of our sales organization. Our philosophy is to invest in countries that show good growth momentum and generate positive cash flow. For example, during 2025 we have expanded our sales teams in our key markets Germany, Spain and UK. Reversely, we have reduced or delayed further investments in lower-potential geographies. With this approach, we ensure that all countries contribute positively to the company over time. We are also placing emphasis on enhancing our field force effectiveness. For example, we have implemented measures to maximize our customer-facing time, improve our customer targeting process, a more effective selling model and more rigorous performance management, including incentive schemes that reward high performance.

During Q4 2025 we report net sales growth of 11% excluding currency effects (5% in reported currency) compared with the same period in 2024. In our main market Germany, sales decreased 6% in Q4 excluding currency effects (10% in reported currency). After strong growth during the first half of the year, sales in Germany were negatively impacted during the second half of the year by markedly fewer patients in intensive care than in 2024. In our other direct markets (Spain, France, UK and Benelux) sales grew by 31% in Q4 excluding currency effects (25% in reported currency). Among these markets, Spain continues to be the top performer in terms of growth. In our distributor markets, sales increased 44% in Q4 excluding currency effects (38% in reported currency). Quarterly fluctuations are to be expected from this customer segment due to their less frequent buying patterns compared to our direct (hospital) customers. We report contract manufacturing revenue of 1.3 MSEK in Q4. Excluding contract manufacturing revenue, we report net sales growth of 10% in Q4 excluding currency effects (4% in reported currency).

For the full year 2025 we report net sales growth of 16% excluding currency effects (12% in reported currency) compared with 2024. Excluding contract manufacturing revenue, we report net sales growth of 12% in 2025 excluding currency effects (8% in reported currency).

Regulatory and pricing/reimbursement approvals in Europe

Our pharmaceutical Sedaconda (isoflurane) has regulatory approval in 15 countries in Europe: Austria, Belgium, Croatia, Denmark, France, Germany, Italy, the Netherlands, Norway, Poland, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. So far, the pharmaceutical has been made available in Germany, France, Spain, Sweden, Norway, Belgium and the Netherlands. In addition, Sedaconda (isoflurane) has been launched in Slovenia via our distributor in the country. Already in 2022, the UK National Institute for Health and Care Excellence (NICE) recommended the Sedaconda ACD as a cost-saving option for delivering inhaled sedation in intensive care. According to NICE, cost modelling had shown cost savings compared with intravenous (IV) sedation of approximately £3,800 per adult patient (30-day time horizon for adult patients needing mechanical ventilation for 24 hours or longer in intensive care). Since 2025, Sedaconda (isoflurane) is also approved for mechanically ventilated children 3-17 years old in 13 European countries. The approval was based on the results of the IsoCOMFORT trial, a randomized active-controlled assessor-blinded study comparing the efficacy and safety of sedation with

inhaled isoflurane, administered via the company's medical device Sedaconda ACD-S, with intravenous midazolam in mechanically ventilated patients 3-17 years old. The authorities assessed that the paediatric extension of the Sedaconda indication brings a significant clinical benefit over existing therapies. Therefore, they granted an additional year of market protection, extending the protection period until 2032. During the protection period, no generic product can be launched for sedation of mechanically ventilated patients in the ICU. In July 2025, the results of the IsoCOMFORT study were published in the scientific journal Lancet Respiratory Medicine.

US clinical program and launch preparations

The US has the highest commercial potential of all markets for Sedana Medical. We estimate the market potential for our inhaled sedation products in the United States to 10-12 BSEK. This figure is approximately three times greater than the combined market potential of our current direct markets. Several factors contribute to this significant opportunity, including the larger population size, a medical practice favoring intubation more than in Europe, and an overall attractive pricing environment. Sedana Medical's US clinical program INSPiRE-ICU completed patient recruitment for the two pivotal INSPiRE-ICU 1 and 2 clinical trials in 2024. The two randomized double-blind clinical studies were designed to confirm and ensure efficacy and safety, based on similar set-up and end-points as our European study (SED001). The total number of patients included in the two studies was 557 (of which 470 randomized and the remainder run-in patients), recruited across 30 clinics. Both INSPiRE-ICU 1 and INSPiRE-ICU 2 met their primary endpoint: to prove that inhaled sedation with isoflurane is an effective sedation method by establishing non-inferiority compared with intravenous sedation using propofol. The safety results were in line with expectations (no unexpected safety concerns arose during the study). In addition, both studies showed a greater reduction of opioid doses compared to the control group and have therefore met their first key secondary endpoint. Wake-up times after end of treatment were short overall, with more than 75% of patients in the isoflurane group waking up within one hour from ending sedation. The safety data, in terms of adverse events and 30-day outcomes, showed an overall similar proportion of patients with serious adverse events in the two study groups and did not reveal any new safety signals for isoflurane. A clinically relevant, but not statistically significant difference in mortality was found in favor of isoflurane. The main study results are publicly available on the clinical trials portal ClinicalTrials.gov, and will be followed by peer-reviewed publications.

We plan to submit our NDA (New Drug Application) to FDA around the middle of 2026. Ahead of our submission, we have been pursuing a strategy of derisking the submission by seeking frequent interactions with the FDA and creating alignment on important aspects of the file before we submit. The most recent milestone in the process was reached in late 2025 the pre-NDA meeting with FDA was completed, and broad alignment was reached with the Agency on the contents of the NDA. FDA confirmed that safety and efficacy data from the clinical trials appear adequate to permit submission and review of the NDA.

Already in early 2023, the FDA granted our clinical program Fast Track Designation. Fast Track is a process designed to facilitate the development and expedite the review of therapies that treat serious conditions and fill an unmet medical need. The purpose is to get important new therapies to the patient faster. Sedana Medical will have the opportunity to discuss with FDA at the time of submission if priority review will apply to Sedaconda, which might have a positive effect on overall timelines.

In April 2025, the U.S. Food and Drug Administration (FDA) authorized our application to initiate an Early Access Program (EAP) for our investigational inhaled sedation therapy. An EAP is designed to allow patients with serious or life-threatening conditions to receive an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available and where the potential patient benefits outweigh the potential risks. The EAP is approved for "difficult-to-sedate" patients, i.e. those who are unable to achieve and maintain target sedation levels with IV sedatives. We will provide our products free of charge to participating hospitals. The first patients are expected to be treated in the first quarter of 2026.

Beyond clinical benefits for patients, the key determinant of a medical product's success in the US market lies in its reimbursement status and impact on customers' economics. Although a variety of inpatient hospital payment mechanisms exist, the DRG ("diagnoses-related groups") system is the dominant one for ventilated patients in the ICU. Under the DRGs, a hospital is paid a preset rate based on the patient's diagnoses and procedures. For mechanically ventilated patients, this will in most cases mean that hospitals will see a tangible positive financial effect if patients wake up fast, spend less time on the ventilator and leave the ICU faster. We have shown these benefits of inhaled sedation in our European trial, and are currently conducting further analysis, including pooling, of our US trial results based on encouraging trends in the data. Moreover, heightened awareness of opioid risks in the US, exacerbated by the opioid crisis with over 100,000 overdose deaths annually, positions our inhaled sedation therapy as a compelling alternative. As US our studies have replicated the significant reduction of opioid use observed in our previous studies, we expect to benefit from the widespread preference for opioid-sparing therapies. The benefits of inhaled sedation are also well aligned with existing treatment recommendations, such as the CDC's "Wake up and Breathe" Collaborative, which is intended to get patients off the ventilator sooner and improve recovery time, opening opportunities to get well positioned in treatment guidelines. Based on these insights, we are highly optimistic about the potential commercial success of inhaled sedation in the US.

As our US clinical trials have been completed, our focus has shifted to finalizing our dossier for NDA submission. In parallel, we are providing scientific exchange and disease awareness, and also engage with key opinion leaders and healthcare professionals to further enhance our understanding of the US market ahead of launch. Sedana Medical expects to be sufficiently financed to achieve US approval, with MSEK 91 in cash at the end of 2025.

Cost management and profitability

We report a gross margin of 72.7% in Q4 2025, compared with 69.5% in Q4 2024 and 71.6% in Q3 2025. In line with our expectation, we see a positive effect on the gross margin during the quarter from reduced cost of goods for our main product

(Sedaconda ACD) following the acquisition of our supplier in Malaysia (Innovatif Cekal). At the same time, the contract manufacturing at Innovatif Cekal has a negative effect on our gross margin at the Group level.

We report operating expenses of MSEK 45 in Q4 2025, which is in line with Q4 2024, as we continue to reduce cost and find efficiencies in our organization to contain cost increases while growing sales. Group EBITDA for the quarter was MSEK 0 compared to MSEK -6 in the same quarter last year, and ex-US EBITDA for the quarter was MSEK 4, compared with MSEK -1 in the same quarter last year. For the full year 2025, group EBITDA was MSEK -10 compared to MSEK -31 in 2024, and ex-US EBITDA was MSEK 6, compared with MSEK -17 in the same quarter last year.

The underlying improvement in profitability continues, and we remain focused on profitable growth opportunities and making sure we manage our resources in a prudent way, to launch in the US backed by a solid foundation in Europe.

ESG sustainability

Sedana Medical aims to be a responsible partner to all customers, suppliers, employees, and other stakeholders, as well as an attractive long-term investment for our shareholders. Sedana Medical's Code of Conduct constitutes a framework for what the company considers to be responsible and appropriate conduct to build a long-term sustainable business. In our Annual Report 2025 we will present updated information on our ESG sustainability work.

New accounting principle introduced in 2025

The accounting principles related to reporting of intercompany currency effects have changed as of 2025. This refers to the currency effects in the Group that arise when translating balance sheet items related to intragroup loans between the parent company and subsidiaries in the Group. In 2024, the effects were reported as part of other operating expenses and income that affected total operating expenses and operating profit. From 2025, the effects are reported as part of net financial items and do not affect operating expenses and operating profit. In this interim report we have also adjusted the corresponding periods of 2024 to provide accurate comparison between periods. The reason for the change is that intra-Group loans are not considered to constitute part of the company's operations and should therefore not affect operating performance metrics.

The operating profit during Q4 2025 amounted to KSEK -6,069 compared to KSEK -11,060 in Q4 2024, which means an improvement by KSEK 4,991. The new accounting principle has led to a positive adjustment in the operating profit in Q4 2025 by KSEK 585 and a negative adjustment to the operating profit in Q4 2024 by KSEK 223. The result after financial items is unchanged.

The operating profit during Jan-Dec 2025 amounted to KSEK -32,156 compared to KSEK -52,179 in Jan-Dec 2024, which means an improvement by KSEK 20,022. The new accounting principle has led to a positive adjustment in the operating profit in Jan-Dec 2025 by KSEK 1,530 and a negative adjustment to the operating profit in Jan-Dec 2024 by KSEK 1,411. The result after financial items is unchanged.

Financial overview

	Oct-Dec		Jan-Dec	
(KSEK)	2025	2024	2025	2024
Net sales	51,774	49,156	200,226	178,754
Gross profit	37,618	34,156	142,709	126,142
Gross margin %	73%	69%	71%	71%
EBITDA	70	-5,516	-10,116	-30,582
EBITDA margin %	0%	-11%	-5%	-17%
EBITDA ex-US	4,047	-1,227	5,944	-16,862
Operating income (EBIT)	-6,069	-11,060	-32,156	-52,179
Operating margin %	-12%	-22%	-16%	-29%
Income after net financial items	-9,963	8,692	-57,264	-9,948
Net income	-10,099	8,498	-59,244	-10,674
Net income margin %	-20%	17%	-30%	-6%
Total assets	954,463	1,019,395	954,463	1,019,395
Equity	900,781	958,227	900,781	958,227
Equity ratio %	94%	94%	94%	94%
Quick ratio %	266%	450%	266%	450%
Debt to equity ratio %	6%	5%	6%	5%
Average number of full-time employees for the period	111	82	108	77
Number of employees at balance date	122	109	122	109
Number of employees and consultants at balance date	127	125	127	125
Average number of shares before dilution	99,336,960	99,336,960	99,336,960	99,336,960
Average number of shares after dilution	99,336,960	99,336,960	99,336,960	99,336,960
Number of shares at balance date before dilution	99,336,960	99,336,960	99,336,960	99,336,960
Number of shares at balance date after dilution	99,336,960	99,336,960	99,336,960	99,336,960
Earnings per share before dilution, SEK	-0.10	0.09	-0.60	-0.11
Earnings per share after dilution, SEK	-0.10	0.09	-0.60	-0.11

Group performance

Net sales

Net sales for the quarter amounted to KSEK 51,774 (49,156), corresponding to an increase of 5 percent. Adjusted for currency effects, the quarter showed an increase of 11 percent.

In our main market, Germany, sales decreased by 10% (6% at constant exchange rates) during the quarter due to significantly fewer intensive care patients than normal for the season. In our Other direct markets sales increased by 25% (31% at constant exchange rates), compared to the same quarter last year. Among our Other direct markets, Spain was the main growth driver during the quarter. Sales in our distributor markets increased by 38% (44% at constant exchange rates).

For the full year, net sales amounted to KSEK 200,226 (178,754), which corresponds to an increase of 12%. Adjusted for currency effects, the increase was 16%.

	Oct-Dec				Jan-Dec			
(KSEK)	2025	2024	%	%*	2025	2024	%	%*
Germany	26,691	29,662	-10%	-6%	110,054	110,459	0%	3%
Other direct sales	19,138	15,328	25%	31%	66,961	52,563	27%	32%
Distributor markets	4,640	3,373	38%	44%	15,073	14,939	1%	4%
Contract manufacturing	1,305	793	n/a	n/a	8,138	793	n/a	n/a
Total net sales	**51,774**	**49,156**	**5%**	**11%**	**200,226**	**178,754**	**12%**	**16%**
Total net sales excluding contract manufacturing	**50,469**	**48,363**	**4%**	**10%**	**192,088**	**177,961**	**8%**	**12%**

**) at constant exchange rates*

Gross profit and margin
The gross profit for the quarter amounted to KSEK 37,618 (34,156), corresponding to a gross margin of 73 (69) percent. The increase in gross margin relates to reduced cost of goods on products produced by Innovatif Cekal, lower freight costs and re-classified general warehousing costs (from cost of goods sold to selling expenses).

For the full year, the gross profit amounted to KSEK 142,709 (126,142), corresponding to a gross margin of 71 (71) percent. During the year, the gross margin has been strengthened by reduced costs of goods on products produced by Innovatif Cekal and the re-classification of general warehousing costs (from cost of goods sold to selling expenses). The re-classification has had a positive effect on the gross profit of KSEK 1,009 in total. At the same time, contract manufacturing has had a negative effect on the gross margin compared to previous years.

Selling expenses
Selling expenses for the quarter amounted to KSEK -25,471 (-28,164). For the full year, selling expenses amounted to KSEK -100,826 (-104,796). The decrease during the quarter and the full year compared to the previous year is mainly due to efficiency improvements in logistics and product distribution as well as in the marketing and distributor organization.

Administrative expenses
Administrative expenses for the quarter amounted to KSEK -13,883 (-11,752).

For the full year, administrative expenses amounted to KSEK -53,830 (-51,799). The increase compared to the previous year is due to increased incentive payments, consolidation of Innovatif Cekal, and the introduction of new administrative systems.

Research and development expenses
Research and development expenses for the quarter amounted to KSEK -5,490 (-4,800). For the full year, research and development expenses amounted to KSEK -20,616 (-20,294).

Other operating income/expenses
Other operating income and expenses mainly consists of unrealized exchange rate differences on operating items. These totaled KSEK 1,157 (-500) for the quarter.

For the full year other operating income and expenses were KSEK 407 (-1,431).

Net financial items and earnings per share
Financial net for the quarter totaled KSEK -3,894 (19,751). The change consists of currency effects on cash and cash equivalents of KSEK -1,934 (16,170), interest on cash and cash equivalents of KSEK 3,304 (11,828) and unrealized exchange rate changes on intra-group receivables and liabilities.

For the full year, the financial net was KSEK -25,108 (42,231). The change consists of currency effects on cash and cash equivalents, primarily USD, of KSEK -23,136 (22,793), interest on cash and cash equivalents of KSEK 3,379 (16,487) and unrealized exchange rate changes on intra-group receivables and liabilities.

The Group's tax expense for the quarter amounted to KSEK -136 (-194). For the full year, the tax expense was KSEK -1,980 (-726). Deferred tax for the quarter was KSEK 672, and for the full year KSEK 715 and derives from Group eliminations of intra-group profits. The Group's tax expenses excluding deferred tax for the quarter amounted to KSEK -809 (-194) and KSEK -2,696 (-726) for the full year, and consist mainly of tax in Spain, Malaysia and Germany.

Consequently, earnings per share amounted to SEK -0.10 (0.09) for the quarter and SEK -0,60 (-0.11) for the full year.

Capitalised development expenditures

Capitalised development expenditures as of December 31, 2025 amounted to KSEK 741,735 compared to KSEK 700,339 at the beginning of the year.

The amount mainly consists of expenses related to clinical studies and registration preparation work in connection with the European market approval of Sedaconda (isoflurane) and in preparation for future market approval in the USA. The increase compared to the beginning of the year amounts to KSEK 41,397 and mainly relates to registration preparation work in the USA, as well as certain investments related to the company's pediatric approval.

The investments for the full year amount to KSEK 60,007, depreciations and amortizations amount to KSEK 16,723 and currency revaluation effects amount to KSEK -1,887. The company sees no indication of impairment risk related to capitalized development expenditures.

Inventory

As of December 31, 2025 inventory amounted to KSEK 37,886 compared to KSEK 45,560 at the beginning of the year. The inventory mainly consists of finished goods and trade goods. The decrease is attributable to increased sales and inventory management after the acquisition of Innovatif Cekal.

Equity and debt

Equity on December 31, 2025 was KSEK 900,781 KSEK, compared to KSEK 958,227 at the beginning of the year. This corresponds to SEK 9.07 (9.65) per share. Equity/assets ratio was 94 percent, compared to 94 percent at the beginning of the year. Debt/equity ratio on December 31 was 6 percent, compared to 5 percent at the beginning of the year.

Cash, cash position and short-term deposits

Cash and cash equivalents decreased by KSEK -20,982 during the quarter and totalled KSEK 90,980 on December 31, 2025 compared to KSEK 111,962 at the beginning of the quarter.

Cash flow from operating activities before changes in working capital amounted to KSEK 173 (6,345) for the quarter. Cash flow from changes in working capital amounted to KSEK -5,419 (937). The negative cash flow from changes in working capital during the quarter is attributable to increased current receivables and decreased current liabilities. Consequently, the cash flow from operating activities amounted to KSEK -5,246 (7,282).

Cash flow from investments in intangible assets for the quarter totalled KSEK -11,037 (-28,750) and mainly consists of development costs for registration preparation work for Sedaconda ACD and Sedaconda (isoflurane) in the US. Investments in subsidiaries amounted to KSEK (0.0) (-24,976). Total cash flow from investing activities for the quarter amounted to KSEK -12,734 (-55,075).

Cash flow from financing activities for the quarter amounted to KSEK -1,067 (-812) and relates to the amortization of lease liabilities.

Currency revaluation differences in cash and cash equivalents amounted to KSEK -1,934 (16,170) during the quarter and are mainly related to cash and cash equivalents in USD. Cash flow per share for the quarter amounted to SEK-0.19 (-0.49).

During the full year, cash and cash equivalents decreased by KSEK -102,979 and amounted to KSEK 90,980 compared to KSEK 193,960 at the beginning of the year.

Cash flow from operating activities before changes in working capital amounted to KSEK -7,451 (-16,759) for the full year. Cash flow from changes in working capital amounted to KSEK -5,329 (4,990). The negative cash flow from changes in working capital during the quarter is attributable to increased current receivables and decreased current liabilities. Consequently, the cash flow from operating activities amounted to KSEK -12,779 (-11,769).

Cash flow from investments in intangible assets amounted to KSEK -60,007 (-172,788) and mainly consists of development costs for registration preparation work for Sedaconda ACD and Sedaconda (isoflurane) in the US, as well as minor investments related to the company's pediatric approval.

Investments in subsidiaries amounted to KSEK -0.6 (-24,976). Repayment of short-term investment was KSEK 0.0 (155,307) and total cash flow from investment activities for the full year amounted to KSEK -63,029 (-44,673).

Cash flow from financing activities for the period amounted to KSEK -4,035 (-3,571) and relates to the amortization of lease liabilities.

Currency revaluation differences in cash and cash equivalents for the period amounted to KSEK -23,136 (22,793) and are mainly related to cash and cash equivalents held in USD.

Cash flow per share for the period was SEK -0.80 (-0.60). Adjusted for repayments and investments in short-term deposits, the cash flow per share amounted to SEK -0.80 (-2.17).

Parent company

The Parent Company’s net sales for the full year totalled KSEK 191,948 (177,736), of which intra-group sales were KSEK 7,179 (7,752).

Operating income for the year totalled KSEK -33,326 (-52,668). Net financial items were KSEK 5,108 (43,828). The change consists of unrealized exchange rate gains on cash and cash equivalents in foreign currency, primarily USD in 2024 and interest received on cash and cash equivalents, as well as unrealized exchange rate changes on intra-group receivables and liabilities.

Shareholders’ equity in the Parent Company on December 31, 2025 totalled KSEK 957,211 compared to KSEK 994,171 at the beginning of the year. This corresponds to a decrease of KSEK 36,960. Share capital totalled KSEK 2,483, compared to KSEK 2,483 at the beginning of the year.

Cash and cash equivalents stood at KSEK 67,706, compared to KSEK 176,424 at the beginning of the year.

The Sedana Medical share

Sedana Medical share was listed on Nasdaq First North Growth Market Stockholm in 2017 and is since January 25, 2023, listed on Nasdaq Stockholm. Market capitalisation at the end of the year was MSEK 1,021.

The price paid for Sedana Medical shares was SEK 19.02 at the start of the year and SEK 10.28 at the end of the year. The lowest closing price during the year was recorded on April 7 and was SEK 6.88. The highest closing price was recorded on January 30 and was SEK 18.84.

Share information

	Oct-Dec		Jan-Dec	
	2025	**2024**	**2025**	**2024**
Net income, KSEK	-10,099	8,498	-59,244	-10,674
Cash flow, KSEK	-19,048	-48,604	-79,843	-60,013
Number of shares at balance date	99,336,960	99,336,960	99,336,960	99,336,960
Average number of shares	99,336,960	99,336,960	99,336,960	99,336,960
Outstanding warrants at balance date	0	824,947	0	824,947
Average number of warrants	0	824,947	618,710	862,060
Share capital at balance date, KSEK	2,483	2,483	2,483	2,483
Equity at balance date, KSEK	900,781	958,227	900,781	958,227
Earnings per share before dilution, SEK	-0.10	0.09	-0.60	-0.11
Earnings per share after dilution, SEK	-0.10	0.09	-0.60	-0.11
Equity per share, SEK	9.07	9.65	9.07	9.65
Cash flow per share, SEK	-0.19	-0.49	-0.80	-0.60

Largest shareholders at the end of the period

	No of shares	**Share**
Linc AB	13,526,519	13.6%
Anders Walldov direkt och indirekt (Brohuvudet AB)	10,000,000	10.1%
Lannebo Kapitalförvaltning	7,984,943	8.0%
Premier Miton Investors	4,966,327	5.0%
Ola Magnusson direkt och indirekt (Magiola AB)	4,312,288	4.3%
Sten Gibeck	4,201,597	4.2%
Avanza Pension	3,906,980	3.9%
Lancelot Asset Management AB	2,462,179	2.5%
Nordnet Pension Funds	2,237,693	2.3%
Nordea Liv & Pension	2,154,241	2.2%
Handelsbanken Funds	1,981,636	2.0%
Livförsäkringsbolaget Skandia	1,966,418	2.0%
Thomas Eklund	1,666,464	1.7%
Skandia Funds	1,614,149	1.6%
Highclere International Investors LLP	1,400,385	1.4%
Fifteen largest shareholders	64,381,819	64.8%
Others	*34,955,141*	*35.2%*
Total	**99,336,960**	**100.0%**

Facts about the share

Trading
Nasdaq Stockholm

No of shares as per Dec 31, 2025
99,336,960

Market cap as per Dec 31, 2025
MSEK 1,021

Ticker
SEDANA

ISIN
SE0015988373

LEI-code
549300FQ3NJRI56LCX32

Certification from the Board of Directors and the CEO

The Board of Directors and the Chief Executive Officer certify that this year-end report presents a true and fair view of the operations, financial position and earnings of the parent company and the Group and describes material risks and uncertainties faced by the parent company and the companies forming part of the Group.

Danderyd February 11, 2026

Claus Bjerre Chairman of the Board	Hilde Furberg Board member	Jens Viebke Board member
Donna Haire Board member	Christoffer Rosenblad Board member	Johannes Doll President and CEO

This year-end report has not been subject to review by the company's auditors.
This document has been prepared in Swedish and English versions. In the event of any discrepancies between the Swedish and English versions, the Swedish version will take precedence.

Contacts and invitation to presentation

Johannes Doll, President and CEO, +46 76 303 66 66
Johan Spetz, CFO, +46 73 036 37 89
ir@sedanamedical.com

Presentation of the year-end report

Sedana Medical presents the year-end report to investors, asset managers, analysts and media on February 12, 2026 at 13.30. The presentation will be held in English and takes place via telephone conference and audio webcast. More information is available at: https://www.finwire.tv/webcast/sedana-medical/year-end-report-2025/

After the presentation, a recorded version of the webcast will be available at: https://sedanamedical.com/investors

Annual report and Annual general meeting

Sedana Medicals annual report will be available on the company's website, www.sedanamedical.com, from April 15, 2026. The annual general meeting will be held on Wednesday May 27, 2026, in Danderyd. More details will be provided in the notice to attend the annual general meeting.

Dividend

The Board of directors proposes that no dividend is paid for the 2025 financial year.

Financial calendar

Annual Report 2025	15 April 2026
Interim Report Q1 2026	23 May 2026
Annual General Meeting 2026	27 May 2026
Interim Report Q2 2026	17 July 2026
Interim Report Q3 2026	22 October 2026

Consolidated income statement, summary

	Oct-Dec		Jan-Dec	
(KSEK)	**2025**	**2024**	**2025**	**2024**
Net sales	51,774	49,156	200,226	178,754
Cost of goods sold	-14,156	-15,000	-57,518	-52,612
Gross profit	**37,618**	**34,156**	**142,709**	**126,142**
Selling expenses	-25,471	-28,164	-100,826	-104,796
Administrative expenses	-13,883	-11,752	-53,830	-51,799
Research and development expenses	-5,490	-4,800	-20,616	-20,294
Other operating income	2,637	827	5,297	2,507
Other operating expenses	-1,480	-1,327	-4,891	-3,938
Operating income	**-6,069**	**-11,060**	**-32,156**	**-52,179**
Net financial items	**-3,894**	**19,751**	**-25,108**	**42,231**
Income before taxes	**-9,963**	**8,692**	**-57,264**	**-9,948**
Income tax	-136	-194	-1,980	-726
Net income	**-10,099**	**8,498**	**-59,244**	**-10,674**
Earnings per share, based on earnings attributable to the parent company's ordinary shareholders:				
Before dilution	-0.10	0.09	-0.60	-0.11
After dilution	-0.10	0.09	-0.60	-0.11
Operating income (EBIT)	**-6,069**	**-11,060**	**-32,156**	**-52,179**
Whereof amortisation of intangible assets	-4,679	-4,188	-16,723	-16,075
Whereof depreciation of tangible assets	-1,460	-1,356	-5,317	-5,522
EBITDA	**70**	**-5,516**	**-10,116**	**-30,582**

Consolidated statement of other comprehensive income, summary

	Oct-Dec		Jan-Dec	
(KSEK)	**2025**	**2024**	**2025**	**2024**
Net income	**-10,099**	**8,498**	**-59,244**	**-10,674**
Other comprehensive income				
Items that can later be reclassified to the income statement:				
Translation differences from foreign operations	2,053	-691	60	-1,593
Other comprehensive income, net after tax	**2,053**	**-691**	**60**	**-1,593**
Total comprehensive income	**-8,046**	**7,806**	**-59,184**	**-12,267**
Total comprehensive income as a whole attributable to the parent company's shareholders	**-8,046**	**7,806**	**-59,184**	**-12,267**

Consolidated balance sheet, summary

(KSEK)	Dec 31, 2025	Dec 31, 2024
ASSETS		
Intangible assets		
Capitalised development expenditure	741,735	700,339
Concessions, patents, licenses, etc.	3,191	3,594
Goodwill[3]	25,284	26,569
Tangible assets		
Machinery and other technical facilities	1,247	588
Equipment, tools and installations	3,295	3,688
Rights of use assets	5,222	6,349
Financial assets		
Other long-term assets	44	47
Deferred tax assets	695	22
Total non-current assets	**780,713**	**741,195**
Inventory	37,868	45,560
Tax receivables	2,284	2,360
Accounts receivable	29,207	26,539
Prepayments and accrued income	4,014	5,855
Other receivables	9,396	3,928
Cash and cash equivalents	90,980	193,960
Total current assets	**173,750**	**278,200**
TOTAL ASSETS	**954,463**	**1,019,395**

(KSEK)	Dec 31, 2025	Dec 31, 2024
EQUITY AND LIABILITIES		
Equity		
Share capital	2,483	2,483
Other contributed capital	1,228,672	1,226,934
Translation difference	-3,732	-3,792
Retained earnings including net profit	-326,643	-267,399
Equity attributable to the parent company's shareholders	**900,781**	**958,227**
Non-current liabilities		
Deferred tax liabilities	64	6
Other provisions	703	157
Non-current lease liabilities	1,885	2,583
Other non-current liabilites	-	6,776
Total non-current liabilities	**2,652**	**9,521**
Current liabilities		
Current lease liabilities	2,812	3,334
Accounts payable	5,270	5,953
Tax liabilities	2,533	3,145
Other liabilities	15,890	10,601
Accrued expenses and prepaid income	24,524	28,615
Total current liabilities	**51,029**	**51,647**
Total liabilities	**53,681**	**61,168**
TOTAL EQUITY AND LIABILITIES	**954,463**	**1,019,395**

[3] See page 22, Acquision of Innovatif Cekal

Consolidated statement of changes in equity, summary

	Equity attributable to parent company shareholders				
(KSEK)	Share capital	Other contributed capital	Translation difference	Retained earnings incl net income	Total
Opening equity at Jan 1, 2024	**2,483**	**1,226,435**	**-2,199**	**-256,724**	**969,995**
Net income	-	-	-	-10,674	-10,674
Other comprehensive income	-	-	-1,593	-	-1,593
Total comprehensive income	**-**	**-**	**-1,593**	**-10,674**	**-12,267**
Transactions with the Group's owners					
Share-based remuneration	-	498	-	-	498
Total transactions with the Group's owners	**-**	**498**	**-**	**-**	**498**
Closing equity at Dec 31, 2024	**2,483**	**1,226,934**	**-3,792**	**-267,398**	**958,227**

(KSEK)	Share capital	Other contributed capital	Translation difference	Retained earnings incl net income	Total
Opening equity at Jan 1, 2025	**2,483**	**1,226,934**	**-3,792**	**-267,398**	**958,227**
Net income	-	-	-	-59,244	-59,244
Other comprehensive income	-	-	60		60
Total comprehensive income	**-**	**-**	**60**	**-59,244**	**-59,184**
Transactions with the Group's owners	-	-	-	-	-
Share-based renumeration	-	1,739	-	-	1,739
Total transactions with the Group's owners	**-**	**1,739**	**-**	**-**	**1,739**
Closing equity at Dec 31, 2025	**2,483**	**1,228,673**	**-3,732**	**-326,643**	**900,781**

Consolidated cash flow statement, summary

(KSEK)	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Operating activities				
Operating income	-6,069	-11,060	-32,156	-52,179
Adjustments for non-cash items				
Depreciations and amortisations	6,139	7,115	22,040	23,167
Exchange rate differences	354	-380	49	-4,224
Other non-cash items	-2,561	-906	2,053	886
Interest received	3,304	11,828	3,379	16,487
Interest paid	-69	-41	-161	-178
Income tax paid	-926	-211	-2,655	-718
Cash flow from operating activities before changes in working capital	**173**	**6,345**	**-7,451**	**-16,759**
Cash flow from changes in working capital				
Increase (-)/ Decrease (+) in inventories	5,862	-888	7,197	2,622
Increase (-)/ Decrease (+) in operating receivables	-6,968	1,141	-4,786	2,201
Increase (+)/ Decrease (-) in operating liabilities	-4,314	684	-7,740	166
Cash flow from operating activities	**-5,246**	**7,282**	**-12,779**	**-11,769**
Investing activities				
Investments in intangible assets	-11,037	-28,750	-60,007	-172,788
Investments in tangible assets	-1,730	-1,349	-2,404	-2,216
Investment in subsidiaries	33	-24,976	-618	-24,976
Sale of current investments	-	-	-	155,307
Cash flow from investing activities	**-12,734**	**-55,075**	**-63,029**	**-44,673**
Financing activities				
Amortisation of leasing liabilities	-1,067	-812	-4,035	-3,571
Cash flow from financing activites	**-1,067**	**-812**	**-4,035**	**-3,571**
Cash flow for the period	**-19,048**	**-48,604**	**-79,843**	**-60,013**
Cash and cash equivalents at the beginning of the period	**111,962**	**226,394**	**193,960**	**231,180**
Currency revaluation difference	-1,934	16,170	-23,136	22,793
Cash and cash equivalents at the end of the period	**90,980**	**193,960**	**90,980**	**193,960**

Parent company income statement, summary

	Oct-Dec		Jan-Dec	
(KSEK)	**2025**	**2024**	**2025**	**2024**
Net sales	50,429	48,268	191,948	177,736
Cost of goods sold	-14,183	-13,913	-53,211	-50,271
Gross profit	**36,246**	**34,355**	**138,737**	**127,465**
Selling expenses	-11,958	-16,168	-48,369	-57,625
Administration costs	-29,989	-28,832	-116,587	-112,560
Research and development costs	-4,930	-4,403	-18,672	-18,224
Other operating income	3,298	2,985	15,495	12,137
Other operating expenses	-906	-1,356	-3,929	-3,861
Operating income	**-8,239**	**-13,419**	**-33,326**	**-52,668**
Net financial items	**4,185**	**19,731**	**-5,108**	**43,828**
Income after net financial items	**-4,054**	**6,311**	**-38,434**	**-8,839**
Group contributions	-1	11	-1	11
Income before tax	**-4,055**	**6,322**	**-38,435**	**-8,828**
Income tax	-413	-	-413	-
Net income	**-4,468**	**6,322**	**-38,848**	**-8,828**

Parent company statement of other comprehensive income, summary

	Oct-Dec		Jan-Dec	
(KSEK)	**2025**	**2024**	**2025**	**2024**
Net income	**-4,468**	**6,322**	**-38,848**	**-8,828**
Other comprehensive income				
Items that can later be reclassified to the income statement:				
Translation differences from foreign operations	39	-56	149	-139
	39	**-56**	**149**	**-139**
Other comprehensive income, net after tax				
Total comprehensive income	**-4,429**	**6,266**	**-38,699**	**-8,968**

Parent company balance sheet, summary

(KSEK)	Dec 31, 2025	Dec 31, 2024
ASSETS		
Intangible assets		
Capitalised development expenditure	705,868	665,834
Tangible assets		
Machinery and other technical facilities	1,247	581
Equipment, tools and installations	2,768	2,977
Financial assets		
Participations in group companies	40,698	40,080
Non-current receivables, group companies	121,073	103,042
Total non-current assets	**871,654**	**812,514**
Current assets		
Inventory	36,661	39,599
Tax receivables	42	2,259
Accounts receivable	24,931	22,606
Receivables, group companies	0	0
Prepaid expenses and accrued income	3,469	5,298
Other receivables	7,599	2,627
Cash and cash equivalents	67,706	176,424
Total current assets	**140,407**	**248,813**
TOTAL ASSETS	**1,012,061**	**1,061,327**

(KSEK)	Dec 31, 2025	Dec 31, 2024
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share capital	2,483	2,483
Fund for capitalised development expenses	703,359	661,075
Non-restricted equity		
Share premium fund	1,228,672	1,226,934
Retained earnings	-938,455	-887,493
Net income	-38,848	-8,828
Equity attributable to the parent company's shareholders	**957,211**	**994,171**
Provisions		
Other provisions	703	157
Total provisions	**703**	**157**
Non-current liabilities		
Liabilities to group companies	12,704	20,483
Other non-current liabiliteis	-	6,776
Total non-current liabilities	**12,704**	**27,260**
Current liabilities		
Accounts payable	3,606	5,904
Liabilities to group companies	3,082	584
Tax debt	-182	1,848
Other liabilities	14,528	9,209
Accrued expenses and deferred income	20,410	22,195
Total current liabilities	**41,444**	**39,740**
Total liabilities	**54,851**	**67,156**
TOTAL EQUITY AND LIABILITIES	**1,012,061**	**1,061,327**

Other information

General information

Sedana Medical (publ), with corporate identity number 556670-2519, is a limited company registered in Sweden with registered office in Danderyd. The address of the head office is Svärdvägen 3A, SE-182 33 Danderyd, Sweden. The object of the company's operations is to develop, manufacture and sell medical devices and pharmaceuticals. Sedana Medical AB is the Parent Company of the Sedana Medical Group. Unless otherwise indicated, all amounts are stated in thousands of Swedish kronor (KSEK). All amounts, unless otherwise indicated, are rounded to the nearest thousand. Figures in brackets relate to the comparative year.
For the Group's financial assets and liabilities, their carrying amount is considered to be a reasonable estimate of fair value as they essentially refer to current receivables and liabilities, so that the discounting effect is insignificant.

Accounting principles

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting. The parent company Interim report has been prepared in accordance with the Annual Accounts Act and Swedish Financial Reporting Board recommendation RFR 2. Applied accounting policies agree with those described in the 2024 Annual Report of Sedana Medical except for the currency effects in the Group that arise when translating balance sheet items related to intragroup loans between the parent company and subsidiaries in the Group. In 2024, the effects were reported as part of other operating expenses and income that affected total operating expenses and operating profit. From 2025, the effects are reported as part of net financial items and do not affect operating expenses and operating profit. None of the other published standards and interpretations that are mandatory for the Group for the financial year 2025 are deemed to have any significant impact on the Group's financial reports.

Important estimates

Estimates and judgements are evaluated regularly and based on historical experience and other factors, including expectations of future events considered reasonable under prevailing circumstances. For further information, see the Group's 2024 Annual Report.

Alternative performance measures

Alternative performance measures relate to financial performance indicators used by the senior management and investors to assess the Group's earnings and financial position which cannot be read or derived directly from the financial statements. These financial performance indicators are intended to facilitate analysis of the Group's development. The alternative performance measures should accordingly be regarded as complementing the financial reporting prepared in accordance with IFRS. The financial performance indicators presented in this report may differ from similar indicators used by other companies. These key ratios that are not defined according to IFRS are also presented in the report because they are considered to constitute important supplementary key ratios for the company's results. For information on these key ratios and how they have been calculated, please see definitions on page 22 and https://sedanamedical.com/investors/financial-reports-presentations/

Risk

Sedana Medical's operations, earnings and financial position are affected by a number of risk factors. These are principally related to demand for medical devices, fluctuating exchange rates and access to funding. More information about Sedana Medical's risks and management of these risks can be found in the 2024 Annual Report on pages 32-34.

Personnel

We are growing the business by re-allocating resources to customer-facing functions while streamlining administration and support functions. The number of employees in the Group excluding Innovatif Cekal at the end of 2025 was 74, and the number of consultants was 3, compared with 80 and 7, respectively, at the end of 2024.
The acquisition of Innovatif Cekal in late 2024 added manufacturing staff, which has resulted in an overall increase in personnel for the Group. The total number of employees in the Group was 112, the total number of temporary manufacturing workers was 12, and the number of consultants was 3 at the end of the period, compared with 109, 9 and 7, respectively, at the end of 2024.

Transactions with related parties

Transactions with related parties are conducted on market terms. In 2024, a consultancy agreement was signed between Sedana Medical and The Eriah Group Inc. Board member Donna Haire is the CEO of The Eriah Group Inc., and the company has invoiced services amounting to KSEK 835 (167) for the period 2025.

Sedana Medical reports compensation and benefits to senior executives in accordance with IAS 19 Employee benefits. Additional information can be found in Sedana Medical's annual report for 2024, page 50-51 and page 58.

Acquisition of Innovatif Cekal

On November 29, 2024, Sedana Medical acquired all shares in Innovatif Cekal, the supplier of the company's main product (Sedaconda ACD). Innovatif Cekal is consolidated into Sedana Medical's financial reports starting from December 1, 2024.

The purpose of the acquisition is to increase our control over the supply chain and improve profitability by reducing the cost of goods. The acquisition will give Sedana Medical direct control over a larger share of the cost of goods sold, which reduces the risks related to future cost fluctuations and supply disruptions. The acquisition enables improved control of the future scale-up of production capacity to meet our growth plans. Over time, when the existing stock at the time of closing has been sold, the deal is expected to add two percentage points to Sedana Medical's EBITDA margin.

The balance sheet of Innovatif Cekal as of November 29, 2024, has been established. The final purchase price for the share's amounts to 34 million SEK on a cash and debt-free basis, adjusted for changes in net working capital, and has been financed through the company's own liquid assets. 75% of the preliminary purchase price was paid on November 29, 2024. The short-term liability related to the final purchase price was settled in May 2025 and the remaining 25% will be paid in Q4, 2026.

(KSEK)	
Purchase consideration	
Cash	32,228
Deferred purchase price	6,776
Total purchase consideration	**39,004**

(KSEK)	
Fair value of acquired assets and assumed liabilities	
Intangible assets	242
Property, plant and equipment	632
Inventory	4,993
Current receivables excluding cash and cash equivalents	4,582
Cash and cash equivalents	4,238
Deferred tax liabilities	-55
Current liabilities	-2,909
Total acquired net assets excluding goodwill	**11,722**
Goodwill	27,283
Total acquired net assets	**39,004**
Minus	
Deferred purchase price	-6,776
Cash	-4,238
Net cash flow from acquisition of operation	**27,990**

Performance based incentive program (LTI 2024)

The Annual General Meeting 2024 decided on a performance-based incentive program LTI 2024 for employees of Sedana Medical, comprising 1,133,810 performance rights in the form of warrants. To ensure the delivery of the warrants and future estimated social security contributions in connection with the exercise of the options, Sedana Medical's subsidiary Sedana Medical Incentive AB has subscribed for 1,490,053 warrants, of which 1,062,803 were allocated to employees as of December 31, 2025. The performance rights have been issued to participants in the program free of charge. Each warrant entitles the holder to acquire one new share in the company at an exercise price of SEK 26.33. The outcome of LTI 2024 is conditional on the company achieving a performance target regarding the average annual growth rate of net sales for the financial years 2025, 2025, and 2026 ("Performance Target"), excluding currency effects. The Performance Target has been determined by the company's board of directors, taking into account the company's business plan and is deemed to be in line with market practice and appropriate. Detailed information on the Performance Target and the outcome of LTI 2024 will be provided during the first half of 2027. If the Performance Target is not fully met, a participant's right to exercise Performance Rights will gradually be reduced to zero, depending on the extent the Performance Target is reached.

At the end of the period, the full utilization of the performance-based incentive program would increase the share capital by KSEK 37 through the issuance of 1,449,053 shares, corresponding to a dilution of 1.5 percent

Performance based incentive program (LTI 2025)

The Annual General Meeting 2025 decided on a performance-based incentive program LTI 2025 for employees of Sedana Medical, comprising 1,133,810 performance rights in the form of warrants. To ensure the delivery of the warrants and future estimated social security contributions in connection with the exercise of the options, Sedana Medical's subsidiary Sedana Medical Incentive AB has subscribed for 1,490,053 warrants, of which 1,133,643 were allocated to employees as of December 31, 2025.

The performance rights have been issued to participants in the program free of charge. Each warrant entitles the holder to acquire one new share in the company at an exercise price of SEK 26.33. The outcome of LTI 2025 is conditional on the company achieving a performance target regarding the average annual growth rate of net sales for the financial years 2025, 2025, and 2026 ("Performance Target"), excluding currency effects. The Performance Target has been determined by the company's board of directors, taking into account the company's business plan and is deemed to be in line with market practice and appropriate. Detailed information on the Performance Target and the outcome of LTI 2025 will be provided during the first half of 2028. If the Performance Target is not fully met, a participant's right to exercise Performance Rights will gradually be reduced to zero, depending on the extent the Performance Target is reached.

At the end of the period, the full utilization of the performance-based incentive program would increase the share capital by KSEK 37 through the issuance of 1,449,053 shares, corresponding to a dilution of 1.5 percent

Warrant programme

At the end of the period Sedana Medical had no outstanding warrants.

Programme	Position	Number of acquired warrants at the beginning of the period	Number of acquired warrants during the period	Number of expired warrants during the period	Number of repurchased warrants during the period	Number of warrants at the end of the period	Terms*	Strike price (SEK)
2022/2025:1	CEO	495,000	-	-495,000	-	-	1:1	46.24
2022/2025:1	Senior management	-	-	-	-	-	1:1	46.24
2022/2025:1	Other employees	-	-	-	-	-	1:1	46.24
2022/2025:1	**Total**	**495,000**	**-**	**-495,000**	**-**	**-**	**1:1**	**46.24**
Exercise period 30 May 2025 - 30 September 2025								
2022/2025:2	CEO	-	-	-	-	-	1:1	46.24
2022/2025:2	Senior management	231,606	-	-231,606	-	-	1:1	46.24
2022/2025:2	Other employees	98,341	-	-98,341	-	-	1:1	46.24
2022/2025:2	**Total**	**329,947**	**-**	**-329,947**	**-**	**-**	**1:1**	**46.24**
Exercise period 30 May 2025 - 30 September 2025								
Totalt	CEO	495,000	-	-495,000	-	**-**		
Totalt	Senior management	231,606	-	-231,606	-	**-**		
Totalt	Other employees	98,341	-	-98,341	-	**-**		
	Total	**824,947**	**-**	**-824,947**	**-**	**-**		

* 1:1 = 1 warrant = 1 share at conversion

Definitions

Average number of full-time employees during the period
Number of full-time employees at the end of each period divided by number of periods

Balance sheet total
Total assets

Cash flow per share
Cash flow for the period divided by average number of shares before dilution

Debt to equity ratio
Total liabilities divided by total equity

EBIT
Operating income/Earnings before interest and taxes

EBITDA
Earnings before interest, taxes, depreciation and amortisation

EBITDA margin
EBITDA divided by net sales

EBITDA ex-US
Operating income (EBIT) less depreciation and write-downs as well as operating expenses attributable to the company's US business

Equity to assets ratio
Total equity divided by total assets

Equity per share
Equity divided by number of shares at the end of the period, before dilution

Gross margin
Gross profit divided by net sales

Net income margin
Net income divided by net sales

Number of employees at the end of the period
Number of employees excluding consultants regardless of employment rate per balance sheet date. Sick leave and parental leave are included. Holidays are not excluded

Number of employees and consultants at the end of the period
Number of employees including consultants regardless of employment rate per balance sheet date. Sick leave and parental leave are included. Holidays are not excluded

Operating margin
Operating income divided by net sales

Quick ratio
Current assets excluding inventories divided by current liabilities

Tax rates for the parent company
2025: 20,6%
2024: 20.6%